Argos Therapeutics (ARGS) Receives Daily Coverage Optimism Rating of 0.24

News stories about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.7082778793578 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Argos Therapeutics (NASDAQ ARGS) opened at $0.16 on Friday. Argos Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $5.68. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29.

TRADEMARK VIOLATION WARNING: “Argos Therapeutics (ARGS) Receives Daily Coverage Optimism Rating of 0.24” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/12/16/argos-therapeutics-args-receives-daily-coverage-optimism-rating-of-0-24.html.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply